ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCYC vs IMRX // RSI-14 & 200D SMA MOMENTUM

Bicycle Therapeutics plc (NASDAQ) VS. Immuneering Corporation (Class A) (NASDAQ) • 15-METRIC TALLY: BCYC 2 — IMRX 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: BCYC
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCYC VS. IMRX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCYC IMRX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -17.49% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 105.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 IMRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 48.1 43.1 +4.94 BCYC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $267.4M $260.1M $7.3M BCYC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCYC REV IMRX REV BCYC GROSS % IMRX GROSS % BCYC FCF IMRX FCF
FY 2025 $72.6M $0 — — -$252.0M -$45.5M
FY 2024 $35.3M $0 — — -$166.0M -$55.1M
FY 2023 $27.0M $0 — — -$60.6M -$49.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCYC // BETA —
IMRX // BETA —